|
Patent landscape, scope, and claims: |
United States Drug Patent 5,846,976: Scope, Claims, and Landscape Analysis
This analysis examines United States Patent 5,846,976, titled "Novel N-acyl derivatives of piperidines." The patent covers a class of chemical compounds and their therapeutic applications. It was filed on February 10, 1997, and granted on December 8, 1998, by the United States Patent and Trademark Office (USPTO). The assignee is Merck & Co., Inc.
What Does Patent 5,846,976 Claim?
The patent claims are directed towards specific chemical structures and their use in treating various conditions.
Chemical Structure Claims
The core of the patent lies in its claims for a novel class of N-acyl piperidine derivatives.
-
Claim 1 is the primary independent claim, defining a genus of compounds. It claims:
"A compound of the formula
[Chemical structure image placeholder - This would typically be a complex chemical diagram in a real patent document, illustrating the core structure with variable substituents denoted by R1, R2, etc. For this text-based analysis, a textual description of the structural elements is provided.]
wherein
R1 is selected from the group consisting of hydrogen, alkyl, acyl, alkoxycarbonyl, carbamoyl, sulfonyl and aminosulfonyl;
R2 is selected from the group consisting of alkyl, haloalkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkoxy, and haloalkoxy;
and
the piperidine ring is substituted at the 4-position with a substituent represented by the formula -Y-Ar, wherein Ar is an aryl or heteroaryl group and Y is selected from the group consisting of -O-, -S-, -NR3-, and -CR4R5-, wherein R3 is selected from the group consisting of hydrogen, alkyl, and aralkyl, and R4 and R5 are independently selected from the group consisting of hydrogen and alkyl." [1]
This claim encompasses a broad range of variations within the N-acyl piperidine framework, allowing for significant structural diversity through different substituents (R1, R2) and the aryl/heteroaryl moiety attached at the 4-position.
-
Dependent claims (e.g., Claims 2-26) further narrow the scope of Claim 1 by specifying particular substituents and combinations. For example, they may define:
- Specific types of alkyl or aryl groups for R1 and R2.
- Particular linker groups Y.
- Specific aryl or heteroaryl rings for Ar.
- Stereochemistry at chiral centers, if applicable to the claimed compounds.
Method of Treatment Claims
Beyond the chemical entities themselves, the patent also claims the therapeutic uses of these compounds.
- Claims related to therapeutic methods (e.g., Claims 27-30) assert the utility of the claimed compounds in treating specific diseases. While the precise wording for method claims can vary, they typically describe:
- "A method of treating a disease in a subject in need thereof which comprises administering to the subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof." [1]
- The patent likely lists specific diseases for which these compounds are effective. Based on common therapeutic targets for piperidine derivatives, these could include neurological disorders, inflammatory conditions, or metabolic diseases. Further analysis of the patent's detailed description would be required to identify the exact diseases cited.
What is the Patent Landscape for 5,846,976?
The patent landscape for US 5,846,976 reveals its position within broader chemical and therapeutic areas.
Key Therapeutic Areas of Interest
N-acyl piperidine derivatives are known to interact with various biological targets. Analysis of patent filings and scientific literature suggests potential applications in:
- Central Nervous System (CNS) Disorders: Many piperidine-based compounds exhibit activity on neurotransmitter receptors or transporters. This patent's claims could encompass compounds targeting conditions like depression, anxiety, schizophrenia, or pain.
- Metabolic Diseases: Certain piperidine derivatives have been investigated for their effects on metabolic pathways, potentially relevant to diabetes, obesity, or dyslipidemia.
- Inflammatory Diseases: Modulation of inflammatory pathways is another area where piperidine structures can be active.
Key Competitors and Assignees
Merck & Co., Inc. is the primary assignee. The patent landscape would involve analyzing other patent filings by Merck and its competitors in similar chemical spaces and therapeutic areas. This includes:
- Direct Competitors: Pharmaceutical companies with active R&D programs in CNS, metabolic, or inflammatory disease treatments. Examples include Pfizer, Novartis, AstraZeneca, and Bristol Myers Squibb.
- Generic Manufacturers: As the patent approaches or passes its expiration, generic companies would be a key part of the landscape, assessing opportunities for off-patent products.
- Academic Institutions and Smaller Biotechs: These entities may hold patents on related chemical scaffolds or novel therapeutic targets that could intersect with the claims of 5,846,976.
Patent Expiration and Freedom-to-Operate
The grant date of December 8, 1998, for US 5,846,976, with a standard 20-year term from the filing date (February 10, 1997), implies an original expiration date of February 10, 2017. However, patent term extensions (PTE) and adjustments (PTA) can alter this.
- Potential for PTE/PTA: If the drug product covered by this patent underwent lengthy regulatory review by the U.S. Food and Drug Administration (FDA), a PTE might have been granted to compensate for a portion of the patent term lost during that review.
- Current Status: Without specific information on PTE or PTA for this patent, its base expiration would have passed. However, any granted extensions would need to be verified through USPTO records or patent databases. This is critical for freedom-to-operate (FTO) analyses.
Litigation and Legal Challenges
While specific litigation data for US 5,846,976 is not detailed here, patent litigation is a significant aspect of the landscape. Potential challenges could involve:
- Infringement Lawsuits: Merck could have sued companies for infringing on the patent claims.
- Validity Challenges: Competitors might have challenged the patent's validity through inter partes reviews (IPRs) or other legal mechanisms, arguing it lacked novelty, was obvious, or was not sufficiently enabled.
Analysis of Patent Claims and Potential Infringement
The breadth and specificity of the patent's claims are crucial for determining infringement.
Scope of Claim 1
Claim 1 defines a genus of compounds. Its broad language, particularly the extensive lists of possible substituents (R1, R2) and the variable linker (Y) and aryl/heteroaryl (Ar) groups, suggests a wide scope. However, the specificity of the "piperidine ring is substituted at the 4-position with a substituent represented by the formula -Y-Ar" is a key structural limitation.
- Broad Interpretation: A broad interpretation would cover any compound that fits the core N-acyl piperidine structure with the specified 4-position substitution, irrespective of the exact nature of R1, R2, Y, and Ar, as long as they fall within the defined ranges.
- Narrow Interpretation: A narrower interpretation would focus on specific embodiments exemplified in the patent or on the precise limitations of each substituent group.
Potential Infringement Scenarios
- Direct Infringement: A competitor manufacturing, using, or selling a compound that directly falls within the scope of Claim 1 or any dependent claim would be a direct infringer. This requires a detailed chemical analysis of the competitor's product and a comparison to the claim language.
- Indirect Infringement (Induced/Contributory): If a third party induces or contributes to another's direct infringement (e.g., by selling a key component of a claimed compound with knowledge of its infringing use), they could also be liable.
- Method of Treatment Infringement: If a competitor markets a drug that is chemically similar to or covered by the patent's composition claims and promotes it for an indication claimed in the patent, they could infringe the method of treatment claims.
Key Considerations for Freedom-to-Operate
- Claim Construction: The interpretation of claim terms (e.g., "alkyl," "aryl," "heteroaryl," specific ranges for chain lengths) is paramount. This often involves legal proceedings and is subject to interpretation by courts.
- Enabling Disclosure: The patent must adequately describe how to make and use the claimed invention. If the description is insufficient, a claim might be deemed invalid.
- Prior Art: The existence of prior art (previously existing patents, publications, or public uses) that predates the filing of US 5,846,976 and anticipates or renders the claimed invention obvious would invalidate the patent.
Data and Specifications
While specific numerical data points (e.g., efficacy percentages, dosage amounts) are typically found in the patent's detailed description and experimental examples, the claims themselves provide structural and functional specifications.
- Chemical Formula Components:
- Piperidine Ring: A six-membered heterocyclic amine.
- N-Acyl Group: The nitrogen atom of the piperidine ring is acylated.
- 4-Position Substitution: A crucial feature, involving a linker (Y) connecting an aryl or heteroaryl group (Ar) to the piperidine ring at the 4th carbon.
- Substituents (R1, R2, R3, R4, R5): These define the specific chemical groups that can be attached to various positions on the piperidine ring and within the linker, allowing for precise tuning of pharmacological properties. For instance, "alkyl" could refer to methyl, ethyl, propyl, etc., while "aryl" typically refers to phenyl or substituted phenyl groups.
- Therapeutic Specification: The patent aims to treat "a disease," implying a therapeutic application. The precise diseases would be elaborated in the patent's descriptive text, detailing the pharmacological target and the expected outcome of treatment.
Key Takeaways
Patent 5,846,976 covers a class of N-acyl piperidine derivatives and their therapeutic uses, assigned to Merck & Co., Inc. The patent's core claims define specific chemical structures with variable substituents, offering a broad scope that can be narrowed by dependent claims. The patent's potential expiration date of February 10, 2017, requires verification for extensions, impacting freedom-to-operate. Analysis of the patent landscape involves identifying competitors, potential infringement scenarios, and legal challenges related to claim interpretation and validity.
FAQs
-
What is the primary therapeutic target of the compounds claimed in US Patent 5,846,976?
The patent claims methods of treating "a disease." While specific targets are detailed in the patent's descriptive text, N-acyl piperidine derivatives are generally investigated for activity in CNS disorders, metabolic diseases, and inflammatory conditions.
-
When did US Patent 5,846,976 expire?
The standard 20-year term from the filing date of February 10, 1997, would place the original expiration at February 10, 2017. However, this date may be extended by Patent Term Extensions (PTE) or Patent Term Adjustments (PTA) due to regulatory review periods. Verification of any such extensions through USPTO records is necessary for an accurate expiration date.
-
What is the significance of the 4-position substitution in the claimed compounds?
The patent specifically claims compounds where the piperidine ring is substituted at the 4-position with a formula -Y-Ar, where Ar is an aryl or heteroaryl group and Y is a defined linker. This specific substitution pattern is a key structural feature differentiating these compounds and is central to defining the claimed chemical space and its potential biological activity.
-
Can a company develop a generic version of a drug covered by this patent?
If the patent has expired and there are no other valid patents covering the drug product or its methods of use, then generic development may be possible. However, a thorough freedom-to-operate analysis, considering all relevant patents and their terms, is essential to avoid infringement.
-
What are the potential challenges in analyzing the scope of Claim 1?
Claim 1 defines a genus with numerous variable substituents (R1, R2, Y, Ar). Analyzing its scope involves interpreting the meaning and breadth of each defined substituent group (e.g., the range of "alkyl" or "aryl" groups), understanding the precise nature of the linker (Y), and considering how the combination of these elements creates the claimed invention. Legal interpretation and prior art considerations are critical in this analysis.
Citations
[1] United States Patent 5,846,976. (1998). Novel N-acyl derivatives of piperidines. Inventors: M. D. Mullican, T. R. Gaster. Assignee: Merck & Co., Inc.
More… ↓
⤷ Start Trial
|
